Table 3.

Knee Injury and Osteoarthritis Outcome Score (KOOS) for patients with dabigatran, nadroparin or rivaroxaban thromboprophylaxis after total knee arthroplasty. Difference between 6 weeks postsurgery and presurgery KOOS and proportion of patients with 10 points or more improvement in KOOS between 6 weeks postsurgery and presurgery

	Dabigatran	Nadroparin	Rivaroxaban	P value
Pain	n=32	n=35	n=35
Difference between 6 weeks postsurgery and presurgery (mean±SD)	25±26	19±22	22±23	0.51
Patients with ≥10 points improvement postsurgery versus presurgery, n (%)	22 (69)	26 (74)	27 (77)	0.78
Symptoms	n=32	n=35	n=35
Difference between 6 weeks postsurgery and presurgery (mean±SD)	12±20	14±20	16±19	0.63
Patients with ≥10 points improvement postsurgery versus presurgery, n (%)	17 (53)	20 (57)	22 (63)	0.72
ADL	n=32	n=35	n=35
Difference between 6 weeks postsurgery and presurgery (mean±SD)	25±20	23±21	21±17	0.75
Patients with ≥10 points improvement postsurgery versus presurgery, n (%)	23 (72)	25 (71)	27 (77)	0.88
Sport and recreation	n=29	n=31	n=29
Difference between 6 weeks postsurgery and presurgery (mean±SD)	24±38	25±41	28±33	0.89
Patients with ≥10 points improvement postsurgery versus presurgery, n (%)	17 (59)	21 (68)	23 (79)	0.24
Quality of life	n=31	n=35	n=35
Difference between 6 weeks postsurgery and presurgery (mean±SD)	26±27	18±20	22±21	0.39
Patients with ≥10 points improvement postsurgery versus presurgery, n (%)	24 (77)	23 (66)	23 (66)	0.55

Due to the explorative nature of this pilot study, all p values are explorativerather than confirmative and are not corrected for multiple testing.

ADL, activities of daily living function.